Priced by the milligram
Every product on the catalogue page is a quantity — a number of milligrams — with a current price against a struck-through anchor. Nothing says how long a quantity lasts, at what dose, or how often it recurs. That is the entire pricing disclosure.
It makes the catalogue easy to read and impossible to compare. A figure per milligram is a real price for a real thing; it is simply not the same kind of number as a monthly rate, and putting the two in one column would publish a comparison the seller never made.
Retatrutide, from the same grid
Alongside the two established molecules sits retatrutide, which has no FDA-approved finished product at all — not a compounded version of an approved drug, but a compound still in clinical development. It is listed with the same add-to-cart button and the same struck-through anchor as the others.
The pen presentations of both established drugs carry a premium over the vials of the same quantity, which is at least the direction the rest of this market runs in.
Three domains, no company
The address most readers would type redirects to a different host, where the catalogue lives. A third, near-identical domain is separately live and does not redirect. Across all of them we found no corporate name at all: the privacy-policy path on the catalogue host returns a 404, and the about page names nobody.
The company FDA addressed its warning letter to does have a name — and that name appears nowhere on any of these sites. A reader who wanted to look up who they were buying from could not do it from the site; only the letter connects the two.
Trust Lab's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $150⛔ a price per 7.92 mg, not per month, published against a struck-through $160.00; converting it to a monthly figure requires a weekly dose this seller never states | September 2026source |
| Semaglutide (compounded) | $200the same 7.92 mg quantity in a pen rather than a vial, against a struck-through $250.00; no period is stated | September 2026source |
| Tirzepatide (compounded) | $250a price per 45 mg, not per month, against a struck-through $300.00 | September 2026source |
| Tirzepatide (compounded) | $320the same 45 mg quantity in a pen, against a struck-through $350.00; no period is stated | September 2026source |
| Retatrutide (compounded) | $450a price per 36 mg of a molecule with no FDA-approved finished product at all, against a struck-through $540.00 | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 198 providers reviewed here are paid partners today; the other 194 are not. See how this works.
See Trust Lab's current price →Good fit if
- Readers who want to see what a GLP-1 costs per milligram rather than per month.
- Buyers comparing the premium a pen carries over a vial of the same quantity.
- People who want no intake, no quiz and no subscription between them and a price.
Look elsewhere if
- Anyone who needs a monthly figure; nothing here is one, and deriving one requires an assumption the seller does not make.
- Readers who need to know which company they are buying from.
- Buyers who want a dose schedule, a clinician or a compounding pharmacy named.
- Anyone who would not knowingly buy a molecule with no approved finished product behind it.
How this review was verified
- Re-read the catalogue page and the about page on 7 September 2026, comparing the requested address to the effective one — which established the cross-host redirect — and running a nonsense path against the catalogue host in the same run, which returned a 404.
- Recorded every product on the grid, its quantity, its current price and its struck-through anchor, rather than the lowest figure.
- Stored all five rows as non-monthly, so no page on this site can print a per-month suffix beside a per-milligram figure.
- Ran a widened corporate-suffix pattern across every cached body on all three related hosts, proved first against a page known to name a company; it returned nothing.
- Screened the entity named in the FDA letter against the live warning-letter datatable with a positive and a negative control in the same invocation, read the three word matches that came back, and re-fetched the correct letter to confirm its title matches the entity, reference number and date.